Neurosense to Evaluate Biological Changes in People with Neurodegenerative Disease
NeuroSense Therapeutics (Nasdaq: NRSN) has announced it will collaborate with Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, to evaluate biological changes occurring in people with neurodegenerative diseases.
This agreement will allow NeuroSense to leverage its extensive experience in biomarker utilization in neurodegenerative diseases, while Lonza provides development, optimization, and qualification of a method measuring biomarkers from NDEs, which will be integrated into the development of NeuroSense’s lead product candidate for ALS, PrimeC.
NDEs are small extracellular vesicles generated by neurons that encapsulate a variety of molecules such as proteins, nucleic acids, and metabolites. NDEs can pass the blood-brain barrier and noninvasively provide a depiction of the current physiological status of neurons in the brain.
Alon Ben-Noon, NeuroSense’s CEO, commented on the collaboration, saying, “We believe this collaboration could be a game-changer for the ALS and neurodegeneration field, as findings in such biomarkers may advance early diagnosis and treatment, as well as expedite the regulatory pathway for new treatments for the millions of people who suffer from neurodegenerative diseases. Collaborating with Lonza enables us to tap into some of the world’s top experts in exosomes-based therapies research to develop another important measure of PrimeC’s efficacy.”
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
